Pre-treatment risk predictors of valproic acid-induced dyslipidemia in pediatric patients with epilepsy.

ABSTRACT: Background: Valproic acid (VPA) stands as one of the most frequently prescribed medications in children with newly diagnosed epilepsy. Despite its infrequent adverse effects within therapeutic range, prolonged VPA usage may result in metabolic disturbances including insulin resistance and dyslipidemia. These metabolic dysregulations in childhood are notably linked to heightened cardiovascular risk in adulthood. Therefore, identification and effective management of dyslipidemia in children hold paramount significance. Methods: In this retrospective cohort study, we explored the potential associations between physiological factors, medication situation, biochemical parameters before the first dose of VPA (baseline) and VPA-induced dyslipidemia (VID) in pediatric patients. Binar

SUBMITTER: Liang T 

PROVIDER: S-EPMC11018995 | biostudies-literature | 2024

REPOSITORIES: biostudies-literature